Literature DB >> 25451023

Comparative Proteome Profiling during Cardiac Hypertrophy and Myocardial Infarction Reveals Altered Glucose Oxidation by Differential Activation of Pyruvate Dehydrogenase E1 Component Subunit β.

Arkadeep Mitra1, Trayambak Basak2, Shadab Ahmad2, Kaberi Datta1, Ritwik Datta1, Shantanu Sengupta2, Sagartirtha Sarkar3.   

Abstract

Cardiac hypertrophy and myocardial infarction (MI) are two etiologically different disease forms with varied pathological characteristics. However, the precise molecular mechanisms and specific causal proteins associated with these diseases are obscure to date. In this study, a comparative cardiac proteome profiling was performed in Wistar rat models for diseased and control (sham) groups using two-dimensional difference gel electrophoresis followed by matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry. Proteins were identified using Protein Pilot™ software (version 4.0) and were subjected to stringent statistical analysis. Alteration of key proteins was validated by Western blot analysis. The differentially expressed protein sets identified in this study were associated with different functional groups, involving various metabolic pathways, stress responses, cytoskeletal organization, apoptotic signaling and other miscellaneous functions. It was further deciphered that altered energy metabolism during hypertrophy in comparison to MI may be predominantly attributed to induced glucose oxidation level, via reduced phosphorylation of pyruvate dehydrogenase E1 component subunit β (PDHE1-B) protein during hypertrophy. This study reports for the first time the global changes in rat cardiac proteome during two etiologically different cardiac diseases and identifies key signaling regulators modulating ontogeny of these two diseases culminating in heart failure. This study also pointed toward differential activation of PDHE1-B that accounts for upregulation of glucose oxidation during hypertrophy. Downstream analysis of altered proteome and the associated modulators would enhance our present knowledge regarding altered pathophysiology of these two etiologically different cardiac disease forms.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2D-DIGE; cardiac hypertrophy; comparative proteome profiling; myocardial infarction

Mesh:

Substances:

Year:  2014        PMID: 25451023     DOI: 10.1016/j.jmb.2014.10.026

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

Review 1.  A multidimensional sight on cardiac failure: uncovered from structural to molecular level.

Authors:  Vijay Urmaliya; Gustavo Franchelli
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 2.  Cardiovascular consequences of metabolic syndrome.

Authors:  Johnathan D Tune; Adam G Goodwill; Daniel J Sassoon; Kieren J Mather
Journal:  Transl Res       Date:  2017-01-09       Impact factor: 7.012

Review 3.  Proteomics in India: the clinical aspect.

Authors:  Somaditya Mukherjee; Arun Bandyopadhyay
Journal:  Clin Proteomics       Date:  2016-11-05       Impact factor: 3.988

4.  HO-1/EBP interaction alleviates cholesterol-induced hypoxia through the activation of the AKT and Nrf2/mTOR pathways and inhibition of carbohydrate metabolism in cardiomyocytes.

Authors:  Xiaohan Jin; Zhongwei Xu; Jin Cao; Rui Yan; Ruicheng Xu; Ruiqiong Ran; Yongqiang Ma; Wei Cai; Rong Fan; Yan Zhang; Xin Zhou; Yuming Li
Journal:  Int J Mol Med       Date:  2017-05-08       Impact factor: 4.101

5.  iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.

Authors:  Huali Chen; Mingjun Wu; Wei Jiang; Xiang Liu; Jun Zhang; Chao Yu
Journal:  Int J Mol Med       Date:  2020-01-22       Impact factor: 4.101

6.  ALDOA protects cardiomyocytes against H/R-induced apoptosis and oxidative stress by regulating the VEGF/Notch 1/Jagged 1 pathway.

Authors:  Gaiying Luo; Rui Wang; Hui Zhou; Xiaoling Liu
Journal:  Mol Cell Biochem       Date:  2020-10-21       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.